Last reviewed · How we verify
N-3 Polyunsaturated Fatty Acids
N-3 polyunsaturated fatty acids reduce triglycerides and modulate inflammatory pathways through incorporation into cell membranes and effects on eicosanoid metabolism.
N-3 polyunsaturated fatty acids reduce triglycerides and modulate inflammatory pathways through incorporation into cell membranes and effects on eicosanoid metabolism. Used for Hypertriglyceridemia, Cardiovascular disease prevention, Inflammation-related conditions.
At a glance
| Generic name | N-3 Polyunsaturated Fatty Acids |
|---|---|
| Also known as | n-3PUFA |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Drug class | Omega-3 fatty acid / Lipid-modifying agent |
| Target | GPR120, GPR40, PPAR-γ, LXR |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
N-3 PUFAs (primarily EPA and DHA) are incorporated into cell membranes where they displace arachidonic acid, reducing production of pro-inflammatory eicosanoids. They also activate G-protein coupled receptors and nuclear receptors (PPAR-γ, LXR) that suppress inflammatory gene expression and improve lipid metabolism, particularly reducing circulating triglycerides and modulating HDL/LDL ratios.
Approved indications
- Hypertriglyceridemia
- Cardiovascular disease prevention
- Inflammation-related conditions
Common side effects
- Gastrointestinal upset (nausea, diarrhea)
- Fishy aftertaste
- Bleeding/bruising (at high doses)
- Headache
Key clinical trials
- n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy (NA)
- NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status (NA)
- Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers (NA)
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Effect of Consuming n-3 PUFAs Rich Foods on Triglyceride Concentration and Lipoprotein Composition (NA)
- Window of Opportunity Study Targeting the Inflammatory Milieu (EARLY_PHASE1)
- Therapeutic Efficacy of Nutritional Supplementation in Cachexia Associated With Chronic Pulmonary Disease (NA)
- Effects of Different Dietary Models on Eating Behavior and Obesity Management in Overweight and Obese Individuals (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: